Cancer Prevention Pharmaceuticals is a clinical stage company developing therapeutics to reduce the risk and recurrence of cancer and rare diseases.

CPP’s innovative technology addresses polyamine metabolism, immune regulation and inflammation to reduce cancer risk and impact other diseases.

These two processes have long been implicated in cancer development but never successfully utilized together to exploit and treat cancer precursors until now.

CPP sponsored the FAP-310 Pivotal Phase 3 Trial of our lead product, CPP-1X/sul, for Familial Adenomatous Polyposis (FAP). CPP-1X/sul has been granted “Fast Track” and “Orphan Drug” designation from FDA. Regulatory pathways are now being pursued

With the National Cancer Institute (NCI) and SWOG, CPP is also co-sponsoring the PACES Phase 3 Trial in colon cancer survivors which is currently recruiting participants.

CPP’s product pipeline includes pharmaco-prevention therapies to address GI cancers, pediatric cancers and early-onset Type 1 diabetes.

CPP’s pharmaco-prevention approach has been used with success in other disease categories such as cardiovascular, neuromuscular, and infectious disease but has yet to be applied to cancer.

About Our Logo


Coal mining lore has it that canaries provided an early warning system to coal miners prior to the advent of sophisticated ventilation systems. Miners brought canaries into mines as a detection system. When the canaries stopped singing and fell off their perch that alerted the miners that gas levels in the mines were high and the miners had to evacuate. The canaries provided the miners with protection before it was too late. That is where our philosophy and the canary’s ability to save lives intersect. CPP seeks to identify and treat cancer precursors before the cancer has a chance to take hold. We are to cancer what canaries were to miners.


© 2019 Cancer Prevention Pharmaceuticals, Inc. All Rights Reserved.                  Legal Notice